267 related articles for article (PubMed ID: 10029609)
1. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
Prantera C; Cottone M; Pallone F; Annese V; Franzè A; Cerutti R; Bianchi Porro G
Gastroenterology; 1999 Mar; 116(3):521-6. PubMed ID: 10029609
[TBL] [Abstract][Full Text] [Related]
2. The suspension of an announced trial on relapse prevention in Crohn's ileitis with a 5-ASA formulation in microgranular form.
Prantera C; Bellinvia S
Dig Liver Dis; 2005 Feb; 37(2):135-6. PubMed ID: 15733528
[No Abstract] [Full Text] [Related]
3. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
[TBL] [Abstract][Full Text] [Related]
4. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
5. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Colombel JF; Lémann M; Cassagnou M; Bouhnik Y; Duclos B; Dupas JL; Notteghem B; Mary JY
Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
[TBL] [Abstract][Full Text] [Related]
6. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
7. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
8. Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.
Gross V; Andus T; Fischbach W; Weber A; Gierend M; Hartmann F; Schölmerich J
Z Gastroenterol; 1995 Oct; 33(10):581-4. PubMed ID: 7502549
[TBL] [Abstract][Full Text] [Related]
9. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
Hanauer SB; Krawitt EL; Robinson M; Rick GG; Safdi MA
Am J Gastroenterol; 1993 Sep; 88(9):1343-51. PubMed ID: 8362827
[TBL] [Abstract][Full Text] [Related]
10. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.
Tromm A; Bunganič I; Tomsová E; Tulassay Z; Lukáš M; Kykal J; Bátovský M; Fixa B; Gabalec L; Safadi R; Kramm HJ; Altorjay I; Löhr H; Koutroubakis I; Bar-Meir S; Stimac D; Schäffeler E; Glasmacher C; Dilger K; Mohrbacher R; Greinwald R;
Gastroenterology; 2011 Feb; 140(2):425-434.e1; quiz e13-4. PubMed ID: 21070781
[TBL] [Abstract][Full Text] [Related]
11. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.
Cammà C; Giunta M; Rosselli M; Cottone M
Gastroenterology; 1997 Nov; 113(5):1465-73. PubMed ID: 9352848
[TBL] [Abstract][Full Text] [Related]
12. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
[TBL] [Abstract][Full Text] [Related]
13. Oral Pentasa in the treatment of active Crohn's disease: A meta-analysis of double-blind, placebo-controlled trials.
Hanauer SB; Strömberg U
Clin Gastroenterol Hepatol; 2004 May; 2(5):379-88. PubMed ID: 15118975
[TBL] [Abstract][Full Text] [Related]
14. Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy.
Tursi A; Brandimarte G; Giorgetti G; Nasi G
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):69-74. PubMed ID: 12544697
[TBL] [Abstract][Full Text] [Related]
15. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
Sutherland LR; Martin F; Bailey RJ; Fedorak RN; Poleski M; Dallaire C; Rossman R; Saibil F; Lariviere L
Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
18. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
19. Mesalamine derivatives in the treatment of Crohn's disease.
Harrell LE; Hanauer SB
Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
[TBL] [Abstract][Full Text] [Related]
20. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease.
Prantera C; Pallone F; Brunetti G; Cottone M; Miglioli M;
Gastroenterology; 1992 Aug; 103(2):363-8. PubMed ID: 1634054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
